Drug Trial Radar · NCT07243379
A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia
Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
495
Planned (sponsor's estimate)
Start
Sep 25, 2025
Primary completion
Dec 31, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Henan Cancer Hospital
- First posted
- Nov 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, real-world observational study. The objective is to evaluate the effectiveness and safety of nanocrystalline megestrol acetate in patients with cancer cachexia in real-world settings. Eligible participants were patients diagnosed with cancer cachexia who were scheduled to receive treatment with nanocrystalline megestrol acetate.
Conditions
- Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia
- Multicenter Observational Study
Interventions
Nanocrystalline Megestrol AcetateDrug
Nanocrystalline Megestrol Acetate oral suspension, with a specification of 125 mg/mL, administered orally at a dose of 5 mL per day (625 mg/day), and the primary endpoint efficacy collection will be conducted in the 4th week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with improved appetite at Week 4 based on the A/CS-12 scale.Time frame: Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital, Affiliated to Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.